

**S**AFETY AND

**T**OLERABILITY OF

**O**MALIZUMAB IN

**P**ATIENTS WITH LUPUS

## VOLUNTEERS NEEDED

Doctors at the National Institutes of Health (NIH) are conducting a research study looking at the safety of Omalizumab (anti-IgE antibody) in patients with mild to moderate lupus activity.



### You may be eligible if you:

- \*Are 18 years old or older
- \*Have mild to moderately active lupus

### You may not be eligible if you:

- \*Are pregnant or breast feeding
- \*Have a history of severe allergic reaction
- \*Have asthma or other medical conditions severely affecting the lungs, heart or liver
- \*Have active hepatitis B, hepatitis C, or HIV
- \*Have an allergy to mouse or human antibodies

### Study Information:

- \*Study is 38 weeks with 15 study visits
- \*Participants will receive omalizumab or a placebo for the first half of the study and then everyone will receive omalizumab
- \*Participants will be monitored with frequent blood and urine sample testing, physical exams, assessment of lupus disease activity, and review of any treatment-related side effects
- \*All study-related medication, tests and procedures are provided at no cost

**Location:** The NIH Clinical Center, America's research hospital, is conveniently located on the Metro Red Line (Medical Center stop) in Bethesda, Maryland. Parking is provided at no cost.

For more information, please call:

1-800-411-1222 TTY number 1-866-411-1010

Se habla español

Online: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Refer to study # 13-AR-0005

NIH... Turning Discovery Into Health®

